Company Profile

Welt Bio-Molecular Pharmaceutical LLC (AKA: WBMP)
Profile last edited on: 2/5/24      CAGE: 502Z1      UEI: Q9NEYZLBH5G3

Business Identifier: Directly active monoclonal antibodies (mAbs) for treatment of cancers and autoimmune diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

59 Whippoorwill Crossing
Armonk, NY 10504
   (914) 844-3687
Location: Single
Congr. District: 17
County: Westchester

Public Profile

Structured around development of highly effective, more tumor-specific monoclonal antibody (mAb) therapies, Welt Bio-Molecular Pharmaceutical LLC personnel are addressing design potent antibodiesable directly to induce a therapeutic effect -- not requiring use of toxic effector compounds -- and which do not cross-react with healthy tissues. Management's judgment is that such an approach allows for development of safer, more effective, and more affordable treatment options for targeted diseases. The firm's lead product -- mAb therapy for B-cell-derived leukemias and lymphomas -- has shown high specificity to, and efficacy in eradicating malignant B-cells. Principals of the firm are working towards completing pre-clinical requirements for this product, while expanding in-house mAb pipeline by discovering and targeting novel, biologically active epitopes in these and other cancers.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Sydney Welt -- President

  David Kostyal -- Partner and CSO

  Rachel Welt -- Chief Laboratory Investigator

Company News

There are no news available.